Limitations of conventional specificity tools have contributed to undetected polyspecificity in antibody drugs. We performed a systematic specificity analysis of preclinical and clinical antibodies and identified a surprisingly high rate of off-target binding throughout the industry, with up to one third of antibody drugs displaying off-target binding.
Our findings across different phases of drug development suggest polyspecificity is a major source of drug attrition, and better tools could help to improve drug approvals and patient safety.
In this webinar, we will discuss the emergence of cell-based protein arrays as an alternative and improved technology to evaluate antibody specificity.
Insights You Don’t Want to Miss:
-
Learn how cell-based protein arrays, including Integral Molecular’s Membrane Proteome Array™ (MPA), enables precise assessment of binding interactions.
- Why the MPA identified off-target interactions that were missed in tissue cross-reactivity studies.
-
How early detection of off-target antibody binding can mitigate drug toxicity and attrition.
Webinar Details
Date: February 27, 2025 | Time: 11 AM, ET
Speakers
Diana Norden is a Senior Scientific Writer at Integral Molecular. Her work primarily focuses on applications of the Membrane Proteome Array, including regulatory requirements for specificity testing. She has written extensively on current standards and best practices for antibody specificity profiling, and recently co-authored a review on emerging trends in biotherapeutic specificity testing that was published in mAbs. Diana earned her Ph.D. from The Ohio State University in 2015.
Kristopher Raghavan is a Senior Application Scientist at Integral Molecular, specializing in the Membrane Proteome Array. Since joining in 2022, he has been instrumental in establishing the MPA as the leading solution for antibody specificity profiling. Kristopher offers technical support, manages projects, and analyzes data for customer projects. He earned his Ph.D.from Drexel University in 2021.
This is a great opportunity to stay ahead of evolving standards in antibody specificity testing.
Register to Secure Your Spot!
We hope you can join us, and we look forward to seeing you there!
In this webinar we will critically review the current methods for generating early developability data, identify existing shortcomings and present innovative high-throughput assays utilizing the plate-based PAIA technology. Attendees will learn about how to use this method which is designed to deliver reliable and unambiguous biophysical developability data, serving as an efficient replacement for time-intensive and laborious HPLC and ELISA methods.
Key Takeaways:
- Review of current methods for early developability data generation.
- Identification of shortcomings in existing techniques.
- Introduction to PAIA high-throughput assays for efficient biophysical data collection.
About Speaker:
Sebastian Giehring earned his PhD in analytical chemistry from the University of Hamburg. He subsequently worked in a scientific role at a spectrometry company before transitioning to a venture capital firm as an investment manager for life sciences. In 2006, he chose to change to the startup sector, taking on various management roles in life science tool companies. In 2014, he invented the PAIA microplate technology and founded PAIA Biotech GmbH, where he has served as CEO ever since.
Register here to secure your spot!
Join us for a webinar hosted by The Antibody Society and mAbs, where Dr. Crescioli and Dr. Reichert will provide an overview of the most important antibody therapeutics expected in 2025. This session will include insights into 2024’s antibody approvals, the latest candidates in regulatory review, and trends in bispecific antibodies and ADCs.
Speakers:
- Dr. Silvia Crescioli: Business Intelligence Creator, The Antibody Society.
- Dr. Janice Reichert: Director of Business Intelligence, The Antibody Society.
Key Takeaways:
- Trends shaping antibody therapeutics in 2025
- Success rates for bispecifics and ADCs
- Projections for upcoming antibody approvals
Register today to secure your spot!
Note: The webinar platform and registration process is managed by Community Brands.
Their privacy policy is here.
